Abstract
Background Hybridoma technology was established in the 2nd half of the 20th century and in the view of current protein production it might seem old-fashioned. Despite, it is commonly used to produce monoclonal antibodies (mAbs) for R & D, clinical diagnostics or medical applications and the demand for mAbs produced by hybridomas is still high. However, compared to CHO, only a few serum-free hybridoma media are available and even less suppliers for chemically defined products are on the market. In this work, a new chemically defined medium and feed were developed to bring hybridoma processes to the next level and to target the existing gap in the market.
Highlights
Hybridoma technology was established in the 2nd half of the 20th century and in the view of current protein production it might seem old-fashioned
Hybridoma cell growth in HybriMACS CD medium was compared to 12 competitor products in the time course of several passages and a final batch cultivation
For a mouse-mouse hybridoma cell line, maximum viable cell density in HybriMACS CD was highest and for a rat-mouse hybridoma cell line second-highest compared to growth in the 12 competitor media, as shown in Figure 1 (A)
Summary
Hybridoma technology was established in the 2nd half of the 20th century and in the view of current protein production it might seem old-fashioned. It is commonly used to produce monoclonal antibodies (mAbs) for R & D, clinical diagnostics or medical applications and the demand for mAbs produced by hybridomas is still high. Compared to CHO, only a few serum-free hybridoma media are available and even less suppliers for chemically defined products are on the market. A new chemically defined medium and feed were developed to bring hybridoma processes to the level and to target the existing gap in the market
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
